NVST vs. XRAY, FTRE, XENE, SHC, PRCT, IRTC, IDYA, JANX, PGNY, and HCM
Should you be buying Envista stock or one of its competitors? The main competitors of Envista include DENTSPLY SIRONA (XRAY), Fortrea (FTRE), Xenon Pharmaceuticals (XENE), Sotera Health (SHC), PROCEPT BioRobotics (PRCT), iRhythm Technologies (IRTC), IDEAYA Biosciences (IDYA), Janux Therapeutics (JANX), Progyny (PGNY), and HUTCHMED (HCM). These companies are all part of the "medical" sector.
DENTSPLY SIRONA (NASDAQ:XRAY) and Envista (NYSE:NVST) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.
Envista has lower revenue, but higher earnings than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.
In the previous week, DENTSPLY SIRONA had 11 more articles in the media than Envista. MarketBeat recorded 16 mentions for DENTSPLY SIRONA and 5 mentions for Envista. Envista's average media sentiment score of 0.24 beat DENTSPLY SIRONA's score of -0.27 indicating that DENTSPLY SIRONA is being referred to more favorably in the media.
DENTSPLY SIRONA received 428 more outperform votes than Envista when rated by MarketBeat users. Likewise, 61.21% of users gave DENTSPLY SIRONA an outperform vote while only 39.44% of users gave Envista an outperform vote.
DENTSPLY SIRONA has a net margin of -2.41% compared to DENTSPLY SIRONA's net margin of -4.70%. Envista's return on equity of 11.54% beat DENTSPLY SIRONA's return on equity.
95.7% of DENTSPLY SIRONA shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by insiders. Comparatively, 1.3% of Envista shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
DENTSPLY SIRONA currently has a consensus price target of $35.22, suggesting a potential upside of 26.29%. Envista has a consensus price target of $25.86, suggesting a potential upside of 39.50%. Given DENTSPLY SIRONA's higher probable upside, analysts clearly believe Envista is more favorable than DENTSPLY SIRONA.
DENTSPLY SIRONA has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Envista has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.
Summary
DENTSPLY SIRONA beats Envista on 13 of the 18 factors compared between the two stocks.
Get Envista News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
